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Summary Human infection with Aeromonas species is uncommon and most often due to trauma
with exposure to contaminatedwater or soil. A 43-year-oldHIV- andhepatitis C virus (HCV)-infected
male, after a two-week course of corticosteroid therapy for an autoimmune anemia, developed
diarrhea, dermatologic manifestations and a multiple organ dysfunction syndrome, resulting in
death. Although stool sampleswere repeatedly negative, two sets of blood cultures obtainedduring
a single peak of fever yielded the post-mortem isolation of a Gram-negative, oxidase-positive, b-
hemolytic bacillus that was identified as Aeromonas sobria. Empiric antibiotic therapy was
unsuccessful. Evaluation of the virulence-associated traits of the clinical isolate (adhesion,
cytotoxicity activity, biofilm production) showed that the strain was a poor producer of recognized
virulence factors, thereby indicating that theunfortunatecoexistenceofHIV infection,HCV-related
liver cirrhosis and corticosteroids played a key role in the clinical course.
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Aeromonas organisms are motile, Gram-negative small rods.
They are facultatively anaerobic, with the ability to colonize
both humans and animals.1 Aeromonas is ubiquitous in
water,2 including chlorinated drinking water; in fact, thesePublished by Elsevier Ltd. All rights reserved.
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tion systems, where flagella facilitate biofilm formation.
Although free cells of Aeromonas might be relatively suscep-
tible to disinfection, populations associated with biofilms
could survive high chlorine doses.3
Of all clinical isolates involved in human infections, 85%
belong to three phenotypically defined species:A. hydrophila,
A. caviae and A. sobria.4 Human infections are most often
associated with open wounds, permitting exposure to con-
taminated fresh or brackish water or soil.5 As Aeromonas has
also been isolated from drinking water, food, salad, ready-to-
eat foods, smoked salmon and vegetables,6 fecal—oral trans-
mission is another significant mode of infection.
Aeromonas species are the causative agents of a variety of
illnesses; although gastrointestinal infections are the most
common presentation,7 extraintestinal localizations, such
as those involving the peritoneum, skin and soft tissues,
meninges, hepatobiliary system, heart, eye and urinary
tract, have also been increasingly reported.4 Aeromonas
bacteremia, an uncommon event that usually affects immu-
nocompromised subjects,8,9 including those with liver cir-
rhosis or malignancy, is a life-threatening condition10 that
can manifest with localized cellulites or ecthyma gangreno-
sum (clostridium-like gangrenous cellulites) and rarely
causes acute rhabdomyolysis11.
ThevirulenceofAeromonas spp. ismultifactorial; virulence
factors are either cell associated or extracellular. Flagella
promote adhesion to epithelial cells and biofilm formation,12
whereas the major extracellular virulence factors include
cytotoxic, cytolytic, hemolytic and enterotoxic proteins.13
Herein, we report a case of severe septicemia caused by
an A. sobria strain in an HIV-positive patient, carefully
evaluating the main virulence traits, including cytotoxicity,
adhesiveness and biofilm formation.
Methods
Bacterial culture
The strain of A. sobria isolated from the patient was grown in
brain heart infusion broth (BHI) (Oxoid, Italy) supplemented
with 0.5% NaCl in 25 ml flasks at 37 8C for 12—18 hours with
shaking at 120 rpm. For the supernatant cytotoxicity assay,
cell-free filtrateswere obtained by centrifugation at 3000 rpm
at 4 8C for 30 min. The supernatant was subsequently filtrated
through a filter with a 0.45 mm pore size (Millipore, Bedford,
MA, USA) and stored at —80 8C until analysis.
Cell line growth
Hep-2 cell (ATCC CCL-23) monolayers were grown in mini-
mum essential medium (MEM, Gibco BRL, Life Technologies,
Rockville, MD, USA), supplemented with 10% fetal bovine
serum (FBS), 1% non-essential amino acids, 5 mM L-glutamine
and 1% penicillin/streptomycin, and maintained in a humi-
dified atmosphere of 5% CO2 at 37 8C.
Biofilm plate assay
The clinical isolate was tested for biofilm formation accord-
ing to the protocol described by Baldassarri et al.14 Briefly,the bacteria were grown overnight at 37 8C in triptic soy
broth supplemented with 1% glucose (TSBG). Each well of a
96-well polystyrene tissue culture plate (Corning Costar,
Milan, Italy) was filled with 180 ml fresh TSBG plus 20 ml of
the A. sobria overnight culture, and plates were incubated
overnight at 37 8C. The culture medium was discarded and
the wells were washed carefully three times with 200 ml
phosphate buffered saline (PBS), avoiding disturbance of
the biofilm on the bottom of the wells. Thereafter, the plates
were dried for 1 hour at 60 8C and stained with 2% Hucker’s
crystal violet for 2 min. Excess stain was removed by rinsing
the plates under tap water and plates were dried for 10 min
at 60 8C. The optical density (OD) was measured at 570 nm in
a Novapath Microplate Reader (Bio-Rad, Italy) to estimate
the amount of biofilm formed. Each assay was performed in
triplicate and repeated at least twice.
Cytotoxicity assays and adhesion
Cytotoxic activity
Hep-2 cells were seeded in 96-well plates (initial inoculum of
5  103 cells ml1) and treated with bacterial supernatant
filtrates after 24 hours; serial twofold dilutions of the super-
natant (starting from 1:2) were added directly to the culture
medium, incubated at 37 8C in 5% CO2 and monitored for
24 hours. Plates were read under an inverted microscope.
The cytotoxic effect was noted by a rounding or detachment
of the cells. The cytotoxic activity titre was expressed as the
reciprocal of the highest dilution of the filtrates affecting at
least 50% of the cells.
Adhesive capacity
The adhesion of the A. sobria isolates to Hep-2 cells was
investigated. For this purpose, Hep-2 cells were seeded on
glass coverslips in 24-well plates (initial inoculum of
5  104 cells ml1), supplemented with A. sobria at a multi-
plicity of infection (MOI) of 100 and incubated for 90 min at
37 8C. Cells were then washed three times in serum-free MEM
to remove nonadherent bacteria, fixed in methanol and
stained with May-Grunwald-Giemsa. Adhesive capacity was
assessed by lightmicroscopy and expressed as the percentage
of cells with more than ten adherent bacteria on the cell
surface. In addition, samples were then fixed with 3.7%
formaldehyde in PBS (pH 7.4) for 10 min at room tempera-
ture. After washing in the same buffer, cells were permea-
bilized with 0.5% Triton X-100 (Sigma, Milan, Italy) in PBS (pH
7.4) for 10 min at room temperature.
To detect the F-actin cytoskeleton, cells were stained
with fluorescein isothiocyanate-phalloidin (Sigma, Italy) and
incubated at 37 8C for 30 min. Cells were then washed in PBS
and coverslips were mounted with glycerol—PBS (2:1).
To analyze the nuclei, permeabilized cells were stained
with Hoechst 33258 (Sigma; working dilution 1:1000) at 37 8C
for 30 min. After washing, coverslips were mounted with
glycerol-phosphate-buffered saline (2:1) and analyzed with
a Nikon Optiphor fluorescence microscope.
Case report
A 43-year-old Italian male with a past history of intravenous
drug abuse was diagnosed as HIV positive for the first time in
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the CD4+ cell count was 239 cells/ml; thereafter, a number of
combination antiretroviral regimens were prescribed accord-
ing to current guidelines. This enabled the patient to main-
tain CD4+ cell count levels of >300 cells/ml and an
undetectable plasma viral load (pVL) without developing
AIDS-related opportunistic infections. As the patient was also
HCV-coinfected (genotype 1a), leading to chronic hepatitis,
interferon (IFN) therapy was prescribed on two occasions.
However, both HCV treatment attempts were unsuccessful;
in February 2005, the patient voluntarily discontinued IFN
after a few administrations because of a sudden onset of
jaundice.
In September 2006, the patient was hospitalized at the
Clinic of Infectious Diseases, Bari with jaundice and severe
weakness. At that time, saquinavir/ritonavir plus tenofovir
plus emtricitabine were being administered; the CD4+ cell
count was 224 cells/ml and pVL was undetectable. On admis-
sion, the patient presented with malaise and fatigue in
addition to jaundice; both the pulse and respiration rate
increased with only slight exertion, and his blood pressure
was 110/70 mmHg. Hepatosplenomegaly was evident on
abdominal examination. Laboratory values were as follows:
hemoglobin 6.4 g/dl, white blood cell count 1.9  109/l,
platelets 47  103/ml. The biochemical profile showed an
elevated total (3.56 mg/dl) and unconjugated (indirect)
(3.14 mg/dl) bilirubin, with moderately elevated alanine
(ALT) and aspartate (AST) transaminases, and a reduction
in the haptoglobin (7 mg/dl). An abdominal ultrasonography
revealed a nodular liver in an advanced stage of cirrhosis,
along with increased echogenicity with irregular-looking
areas. As the direct Coombs test, antinuclear antibodies
(ANAs) and anti-neutrophil cytoplasmic antibodies (ANCAs)
were all positive, an autoimmune anemia was diagnosed.
Therefore, corticosteroid therapy (methylprednisolone
2 mg/kg/day, total 125 mg) and blood transfusions were
initiated, resulting in increased hemoglobin values (10 mg/
dl) within a few days; however, the patient developed dia-
betes, thus requiring insulin administration. Ten days after
beginning immunosuppressive therapy, the patient mani-
fested ascites and edema of the ankles, and therefore diure-
tics were added to the therapy. Two weeks later, the patient
complained of watery diarrhea without fever or any addi-
tional symptoms. Stool samples were repeatedly negative for
protozoa such as Giardia, Cryptosporidium and Entamoeba.
Acid-fast stains for Cyclospora, Isospora and Mycobacterium
species were also negative, and other enteric bacterial
pathogens, such as Salmonella, Shigella, Yersinia, Campylo-
bacter jejuni, Vibrio and Escherichia coli, were also absent in
multiple stool samples. Testing for Clostridium difficile tox-
ins (A and B) was negative, and the presence of Candida spp.
in fecal samples was also excluded. Lastly, no evidence of
Cytomegalovirus infection was found. Rehydration, lopera-
mide and octreotide were administered, without improve-
ment.
Three days after the onset of diarrhea, the patient began
to complain of abdominal pain; at this time, an abdominal CT
scan demonstrated dilated loops, primarily in the transverse
colon, with air levels that were compatible with the diar-
rheic alvus. A petechial eruption appeared on the left leg
and the patient had a single peak of fever, during which two
sets of blood cultures (Organon Teknica, Milan, Italy) wereperformed. Thereafter, empiric therapy withmetronidazole
and ceftriaxone was initiated. Blood chemistry (red and
white blood cell counts, serum creatinine, urea and elec-
trolytes, prothrombin and partial thromboplastin time,
myoglobin, lactate dehydrogenase [LDH] and creatine phos-
phokinase [CPK], glycemia and transaminases) was within
the normal range. Platelets were 58 000/ml, but previous
platelet counts (since 2003) had always been <100 000/ml.
The following day, a rapid succession of events provoked
an irreversible deterioration of the patient’s condition. The
patient awoke with severe pain in both calves, which was
initially disproportionate to physical findings, but continued
to spread to the thighs; thereafter, an intense redness and
induration of the lower extremities was followed by violac-
eous bullae formation. These circumscribed (>2 cm) tense
lesions contained serous fluid and were initially localized on
the right calf, but suddenly became generalized in both legs.
A Doppler study of the legs was normal. His temperature was
persistently normal, whereas the patient soon developed
hypotension with tachypnea. At this time, laboratory values
were as follows: white blood cell count 0.36  109/l, plate-
lets 18 000/ml, PT (prothrombin) ratio 2.59, CPK 5570 U/l,
myoglobin 4949 ng/ml. Acute renal failure, characterized by
oliguria with retention of nitrogen (urea: 157 mg/dl and
creatinine: 2.7 mg/dl), and metabolic acidosis, consistent
with septic shock, developed. The patient’s condition rapidly
worsened; bullae on the legs became hemorrhagic, the
intense myalgia required morphine and a multiple organ
dysfunction syndrome developed, leading to death.
The results of the blood cultures were available only post-
mortem. Positivity was noted after 24 hours of incubation;
subcultures on blood agar produced colonies of a Gram-
negative, oxidase-positive, b-hemolytic bacillus. The strain
was identified as Aeromonas hydrophila group (MicroScan
WalkAway, Dade Behring, Milan, Italy). The use of API test
strips (API 20 NE, bioMe`rieux, Italy) performed at two dif-
ferent centers yielded a code (7177755/7176755) compatible
with an optimum identification of A. sobria.
An antimicrobial susceptibility profile was performed by
MicroScan WalkAway, Dade Behring, Milan, Italy. The strain
was susceptible to amikacin, gentamycin, tobramycin, cefe-
pime, ciprofloxacin, levofloxacin lomefloxacin, sulfamethox-
azole-trimethoprim and chloramphenicol. The strain was
resistant to b-lactam antibiotics because of production of
an inducible b-lactamase. Extended b-lactamases were not
detected by E Test (AB Biodisk, Biolife, Italy). Resistance to
imipenem and meropenem were also observed.
In vitro experimental results on the expression of viru-
lence traits of the clinical isolate of A. sobria were as
follows: according to the measured OD values, the clinical
isolate was found to be unable to form a biofilm. Fluores-
cence microscopy observation of control Hep-2 cells
(Figure 1A) and cells treated with bacterial supernatant
(Figure 1B) showed a marked reduction in the number
of still-adhered Hep-2 cells. This effect, which was still
detectable at the supernatant dilution of 1:2, presumably
reflects the Hep-2 cell response to bacterial toxic agents
released in the supernatant. The isolated strain did not
show adhesive properties on Hep-2 cells and no evidence of
significant morphological changes at the cytoskeletal level
was revealed. Regarding the cell nuclei, no morphological
alterations were observed.
Figure 1 Fluorescence micrographs of (A) untreated Hep-2 cells and (B) cells treated with A. hydrophila supernatant stained for
detection of F-actin cytoskeleton (green) and nuclei (blue). Fluorescence microscopy observation of control Hep-2 cells and cells
treated with bacterial supernatant showed a marked reduction in the number of still-adhered Hep-2 cells. This effect, which is still
detectable at the supernatant dilution of 1:2, presumably reflects the Hep-2 cell response to bacterial toxic agents released in the
supernatant. Regarding the cell nuclei, no morphological alterations were observed.
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Aeromonas is a significant human pathogen that causes a
variety of intestinal and extraintestinal infections both in
healthy hosts and in immunocompromised subjects.15 In
vulnerable individuals with underlying diseases, such as can-
cer, leukemias, liver cirrhosis, hepatobiliary diseases and
diabetes,11,16 Aeromonas infections that are either asso-
ciated with wounds involving exposure to an aquatic envir-
onment or disseminated from the gastrointestinal tract can
lead to bacteremia, resulting in a 30—70% fatality rate.5
To the best of our knowledge, little or no data exist
regarding Aeromonas and HIV infection, thus indicating that
HIV is not a major predisposing condition. Overall, three
cases of Aeromonas infection have been reported in HIV-
positive subjects: two patients with Aeromonas septicemia
and concomitant leukaemia,15 and one patient with acute
colitis.17 Interestingly, among HIV-infected persons, 40—80%
of diarrheal illnesses, whose prevalence in Western countries
ranges from 42 to 90%,18 are caused by infective agents,
mainly bacteria.19 However, Sanchez et al.20 described
trends in the occurrence of bacterial diarrhea among HIV-
infected individuals during a ten-year period, demonstrating
that the frequency of Aeromonas infection was 1.6% for all
Aeromonas species compared to 54.4% for Clostridium spe-
cies. Moreover, Suthienkul et al.21 reported that Aeromonas
diarrhea was present in 4.6% of AIDS patients and 8.3% of non-
AIDS patients in Thailand, thereby confirming that Aeromo-
nas diarrhea is not of particular concern in HIV-infected
individuals. Our patient was an HIV-positive subject, but also
presented with HCV-related liver cirrhosis. Also, corticoster-
oids prescribed for the autoimmune anemia provoked the
development of diabetes. Therefore, it can be presumed that
the coexistence of these conditions played a crucial role in
the onset and severity of the clinical course.
For patientswith diarrhea and underlying diseases such as
those in our patient, the translocation of Aeromonas across
the bowel is the most likely source of bacteremia15. Bacter-
ial translocation is promoted by several factors, including
overgrowth of intestinal bacteria, chemotherapy, suppres-sion of the host immune defenses and conditions that affect
the liver22. However, only 5% of patients with a positive
blood culture have diarrhea,23 possibly secondary to the
ingestion of contaminated water or food. The source of
bacteremia in our patient was unclear; although diarrhea
was the first manifestation, multiple stool samples did not
yield Aeromonas, and we cannot assert that bacteremia was
the consequence of microbial translocation from the intest-
inal tract into the bloodstream. Likewise unclear was the
modeof entry of the bacterium. The patient had nohistory of
previous contact with potentially contaminated water or
food products, and at the time when he manifested his
symptoms, he had been hospitalized for about one month.
Although we are aware that the possibility of a nosocomial
infection due to Aeromonas does exist, as a consequence of
intravascular catheter implant,24 medicinal leech therapy,
ready-to-eat foods25 or water, no other infections due to the
same bacterial strain of Aeromonas occurred in our hospital
during this time and certainly our patient was not subjected
to leeching.
Both host and microbial factors, such as infectious dose
and expression of virulence properties, can affect the ability
of Aeromonas to cause disease. The virulence of Aeromonas
spp. is multifactorial; in fact, Aeromonas spp. possess a
number of virulence properties considered responsible for
intestinal and extraintestinal infections in human beings.
Factors contributing to virulence include cytotonic and cyto-
toxic enterotoxins, the translocation capacity (as demon-
strated in a cellular culture model), cytotoxicity on Vero
cells, proteases, hemolysins (which, in the case of A. sobria,
are major virulence factors with both hemolytic and enter-
otoxic activity and cause diarrhea by activating HCO3 secre-
tion), lipases, adhesins, agglutinins and various hydrolytic
enzymes.13 More recently, a cytotoxin named vacuolating
cytotoxic factor, which provokes the death of Vero cells, has
been described in A. sobria.26
In our case, the clinical isolate failed to demonstrate
adherence, which is a crucial step for most microbial infec-
tions, including Aeromonas infection, because it protects the
microorganism from elimination by host defense mechan-
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between bacterial adherence in vitro and infectivity in
vivo.27 Our isolate was also unable to form biofilms; this
capacity represents an important mechanism of bacterial
escape, as Aeromonas in biofilms could resist disinfection
and persist for long periods of time. Lastly, when assayed on
Hep-2 cells, the isolate did not exhibit any in vitro cytotoxic
activity. Overall, these results emphasize the limited viru-
lence of the isolate obtained from our patient during bacter-
emia and do not seem to correlate the isolate with diarrhea,
as the production of cytotoxins, enterotoxins and hemolysins
by Aeromonas spp. is normally implicated in the pathogenesis
of diarrhea. Alternatively, unrecognized host factors have a
pivotal role in determining the conditions in which virulence
factors are expressed and disease occurs.
Aeromonas spp. are generally susceptible to the majority
of antibiotics active against Gram-negative bacilli; however,
increasing antimicrobial resistance among Aeromonas spp.
has been observed worldwide. In the case described herein,
the strain was resistant to b-lactam antibiotics, including
carbapenems. This finding is consistent with the described
ability of Aeromonas spp. to produce three different indu-
cible b-lactamases, including a carbapenemase,28 thereby
indicating that b-lactams should be used with caution for the
treatment of Aeromonas infections. As expected, our isolate
retained its susceptibility to aminoglycosides,29 and also to
fluoroquinolones, sulfamethoxazole-trimethoprim and chlor-
amphenicol, contrary to previously published studies.30,31 In
general, available data regarding Aeromonas susceptibility
seem to indicate a variable pattern of resistance to anti-
biotics, depending on the source and country of isolation, and
the Aeromonas species, thus reinforcing the importance of
obtaining a susceptibility test before deciding the correct
treatment regimen.
Based on our experience and that of the few other recent
case reports, clinicians should ask microbiologists to verify
the possible involvement of Aeromonas spp. as the causa-
tive agent of infection in immunocompromised patients
with enteritis and/or those presenting significant muscle
pain. The use of selective media for Aeromonas must be
recommended in order to increase the isolation rate from
diarrheal stool.
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